Document ID: chunk:federal_register_of_legislation:F2021L00618:reg:9:p1
Version: federal_register_of_legislation:F2021L00618
Segment Type: reg
Provision Reference: reg 9 (pt 1/2)
Character Range: 3723–6590

9               Factors that must exist
At least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting IgA nephropathy or death from IgA nephropathy with the circumstances of a person's relevant service:
(1)          having cirrhosis of the liver or chronic liver disease at the time of the clinical onset of IgA nephropathy;
Note: chronic liver disease is defined in the Schedule 1 - Dictionary.
(2)          having an autoimmune disease from the specified list of autoimmune diseases at the time of the clinical onset of IgA nephropathy;
Note: specified list of autoimmune diseases is defined in the Schedule 1 - Dictionary.
(3)          having a malignant neoplasm at the time of the clinical onset of IgA nephropathy;
(4)          having an infection from the specified list of infections within the 30 days before the clinical onset of IgA nephropathy;
Note: specified list of infections is defined in the Schedule 1 - Dictionary.
(5)          taking a drug which is associated in the individual with the clinical onset of IgA nephropathy during drug therapy and either:
(a)          the improvement of IgA nephropathy within 3 months of discontinuing or tapering drug therapy; or
(b)          the redevelopment of IgA nephropathy on rechallenge with the same drug;
where taking the drug continued for at least the 7 days before the clinical onset of IgA nephropathy;
(6)          taking a biologic agent for the treatment of cancer or autoimmune disease for at least the 7 days before the clinical onset of IgA nephropathy;
Note: biologic agent is defined in the Schedule 1 - Dictionary.
(7)          undergoing kidney transplantation before the clinical onset of IgA nephropathy;
(8)          having cirrhosis of the liver or chronic liver disease at the time of the clinical worsening of IgA nephropathy;
Note: chronic liver disease is defined in the Schedule 1 - Dictionary.
(9)          having an autoimmune disease from the specified list of autoimmune diseases at the time of the clinical worsening of IgA nephropathy;
Note: specified list of autoimmune diseases is defined in the Schedule 1 - Dictionary.
(10)      having a malignant neoplasm at the time of the clinical worsening of IgA nephropathy;
(11)      having an infection from the specified list of infections within the 30 days before the clinical worsening of IgA nephropathy;
Note: specified list of infections is defined in the Schedule 1 - Dictionary.
(12)      taking a drug which is associated in the individual with the clinical worsening of IgA nephropathy during drug therapy and either:
(a)          the improvement of IgA nephropathy within 3 months of discontinuing or tapering drug therapy; or
(b)          the clinical worsening of IgA nephropathy on rechallenge with the same drug; and
where taking the